Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 10 12 2019
accepted: 09 03 2020
entrez: 16 4 2020
pubmed: 16 4 2020
medline: 7 7 2020
Statut: epublish

Résumé

Understanding immune responses to native antigens in response to natural infections can lead to improved approaches to vaccination. This study sought to characterize the humoral immune response to anthrax toxin components, capsule and spore antigens in individuals (n = 46) from the Kayseri and Malatya regions of Turkey who had recovered from mild or severe forms of cutaneous anthrax infection, compared to regional healthy controls (n = 20). IgG antibodies to each toxin component, the poly-γ-D-glutamic acid capsule, the Bacillus collagen-like protein of anthracis (BclA) spore antigen, and the spore carbohydrate anthrose, were detected in the cases, with anthrax toxin neutralization and responses to Protective Antigen (PA) and Lethal Factor (LF) being higher following severe forms of the disease. Significant correlative relationships among responses to PA, LF, Edema Factor (EF) and capsule were observed among the cases. Though some regional control sera exhibited binding to a subset of the tested antigens, these samples did not neutralize anthrax toxins and lacked correlative relationships among antigen binding specificities observed in the cases. Comparison of serum binding to overlapping decapeptides covering the entire length of PA, LF and EF proteins in 26 cases compared to 8 regional controls revealed that anthrax toxin-neutralizing antibody responses elicited following natural cutaneous anthrax infection are directed to conformational epitopes. These studies support the concept of vaccination approaches that preserve conformational epitopes.

Identifiants

pubmed: 32294093
doi: 10.1371/journal.pone.0230782
pii: PONE-D-19-34198
pmc: PMC7159215
doi:

Substances chimiques

Anthrax Vaccines 0
Antibodies, Bacterial 0
Antibodies, Neutralizing 0
Antigens, Bacterial 0
Bacterial Toxins 0
Epitopes 0
Immunoglobulin G 0
anthrax toxin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0230782

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM103510
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007633
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI062629
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Public Health. 2010;3(3):98-105
pubmed: 20869669
Org Biomol Chem. 2009 Dec 21;7(24):5184-99
pubmed: 20024115
Infect Immun. 2011 Aug;79(8):3302-8
pubmed: 21576335
Mol Aspects Med. 2009 Dec;30(6):456-66
pubmed: 19560486
Clin Vaccine Immunol. 2012 Aug;19(8):1238-42
pubmed: 22718130
PLoS One. 2016 Mar 23;11(3):e0148713
pubmed: 27007118
Vaccine. 2015 Jun 4;33(24):2771-7
pubmed: 25917676
Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):839-42
pubmed: 1468425
Vaccine. 2011 May 9;29(20):3670-8
pubmed: 21420416
Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6
pubmed: 6285339
Annu Rev Microbiol. 2001;55:647-71
pubmed: 11544370
Clin Vaccine Immunol. 2013 Feb;20(2):282-6
pubmed: 23269414
Chemistry. 2006 Dec 13;12(36):9136-49
pubmed: 17133642
Infect Immun. 1986 May;52(2):356-63
pubmed: 3084381
Clin Vaccine Immunol. 2017 Nov 6;24(11):
pubmed: 28877928
J Gen Microbiol. 1961 Sep;26:49-63
pubmed: 13916257
PLoS Pathog. 2014 May 01;10(5):e1004085
pubmed: 24788397
Clin Vaccine Immunol. 2014 Nov;21(11):1512-20
pubmed: 25185577
Annu Rev Microbiol. 2015;69:185-208
pubmed: 26195305
J Biol Chem. 2006 Feb 24;281(8):4831-43
pubmed: 16293624
Am J Trop Med Hyg. 1988 Dec;39(6):575-81
pubmed: 3144920
Epidemiol Infect. 2012 May;140(5):879-86
pubmed: 21835070
Am J Hyg. 1960 Jul;72:32-7
pubmed: 14427621
MMWR Recomm Rep. 2010 Jul 23;59(RR-6):1-30
pubmed: 20651644
N Engl J Med. 2001 Nov 29;345(22):1621-6
pubmed: 11704686
Euro Surveill. 2014 Aug 14;19(32):
pubmed: 25139073
J Infect Dis. 1989 Oct;160(4):706-10
pubmed: 2507648
Vaccine. 2017 Jun 8;35(26):3416-3422
pubmed: 28504191
Med Microbiol Immunol. 1988;177(5):293-303
pubmed: 3139974
Clin Vaccine Immunol. 2011 May;18(5):743-8
pubmed: 21389148
J Appl Microbiol. 2007 Nov;103(5):1453-60
pubmed: 17953556
Cell Biosci. 2015 Apr 26;5:20
pubmed: 26075052
Nature. 2001 Nov 8;414(6860):225-9
pubmed: 11700562
Vaccine. 1991 Aug;9(8):533-9
pubmed: 1771966
J Gen Microbiol. 1960 Feb;22:206-18
pubmed: 13833788
J Infect Dis. 2007 Jan 15;195(2):174-84
pubmed: 17191162
Infect Immun. 2007 Nov;75(11):5240-7
pubmed: 17785478
Clin Vaccine Immunol. 2010 Nov;17(11):1753-62
pubmed: 20739500
Emerg Infect Dis. 2002 Oct;8(10):1103-10
pubmed: 12396924
Vaccine. 2012 Jun 13;30(28):4276-83
pubmed: 22425791
J Infect Dis. 2004 Oct 1;190(7):1228-36
pubmed: 15346332
Biochem J. 1956 Jul;63(3):437-42
pubmed: 13341899
FEMS Immunol Med Microbiol. 2011 Jul;62(2):164-72
pubmed: 21401726
J Med Microbiol. 2012 Oct;61(Pt 10):1380-1392
pubmed: 22767539
Scand J Immunol. 1994 Jun;39(6):557-66
pubmed: 7516572
J Infect Dis. 2011 Nov;204(9):1321-7
pubmed: 21908727
Vaccine. 2016 Jul 25;34(34):4012-6
pubmed: 27329184
J Immunol. 2010 Apr 1;184(7):3814-21
pubmed: 20208010
N Engl J Med. 1999 Sep 9;341(11):815-26
pubmed: 10477781
J Immunol Methods. 2008 Apr 20;333(1-2):89-106
pubmed: 18304568
Emerg Infect Dis. 2009 Oct;15(10):1637-40
pubmed: 19861061
J Infect Dis. 2010 Jul 15;202(2):251-60
pubmed: 20533877
Clin Exp Immunol. 2013 Jul;173(1):84-91
pubmed: 23607659
Emerg Infect Dis. 2001 Nov-Dec;7(6):933-44
pubmed: 11747719
J Appl Microbiol. 2009 May;106(5):1618-28
pubmed: 19226390
Vaccine. 2007 Feb 26;25(10):1780-8
pubmed: 17229495
Mol Microbiol. 1994 Sep;13(6):1093-100
pubmed: 7854123

Auteurs

Eric K Dumas (EK)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Hayati Demiraslan (H)

Department of Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Rebecca J Ingram (RJ)

Centre for Infection and Immunity, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.

Rebecca M Sparks (RM)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.

Emily Muns (E)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.

Adriana Zamora (A)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.

Jason Larabee (J)

Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Lori Garman (L)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Jimmy D Ballard (JD)

Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Geert-Jan Boons (GJ)

Complex Carbohydrate Research Center and Department of Chemistry, University of Georgia, Athens, Georgia, United States of America.
Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.

Judith A James (JA)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Departments of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Uner Kayabas (U)

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Inonu University, Malatya, Turkey.

Mehmet Doganay (M)

Department of Infectious Diseases, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

A Darise Farris (AD)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH